lanreotide (somatuline depot) Report issue

Biologics Peptide Orphan Drug FDA Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Lanreotide is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome. It is a long-acting analog of somatostatin. It is available in several countries, including the United Kingdom, Australia and Canada, and was approved for sale in the United States by the Food and Drug Administration on August 30, 2007. Lanreotide was developed in the lab of Dr. David H. Coy, School of Medicine. Dr. Coy serves as Director of the Peptide Laboratory. Lanreotide (as lanreotide acetate) is manufactured by Ipsen, and marketed under the trade name Somatuline. The mechanism of action of lanreotide is believed to be similar to that of natural somatostatin. Lanreotide has a high affinity for human somatostatin receptors (SSTR) 2 and 5 and a reduced binding affinity for human SSTR1, 3, and 4. Activity at human SSTR 2 and 5 is the primary mechanism believed responsible for GH inhibition. Like somatostatin, lanreotide is an inhibitor of various endocrine, neuroendocrine, exocrine and paracrine functions. Lanreotide inhibits the basal secretion of motilin, gastric inhibitory peptide and pancreatic polypeptide, but has no significant effect on the secretion of secretin. Lanreotide inhibits postprandial secretion of pancreatic polypeptide, gastrin and cholecystokinin (CCK). In healthy subjects, lanreotide produces a reduction and a delay in post-prandial insulin secretion, resulting in transient, mild glucose intolerance.   NCATS

Chemistry

  • SMILES: CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccc3ccccc3c2)CSSC[C@@H](C(=O)N[C@H](C(N)=O)[C@@H](C)O)NC1=O
  • InChIKey: PUDHBTGHUJUUFI-SCTWWAJVSA-N
  • Mol. Mass: 1096.35
  • ALogP: Missing data
  • ChEMBL Molecules:
    lanreotide  
    lanreotide acetate  
More Chemistry

Pharmacology

Drug Pricing (per unit)

Australia

$846.9997 - $1410.6118

United States

$2698.4050 - $3132.6400
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

188re-lanreotide | 2-naphthylalanyl-cyclo(cysteinyl-tyrosyl-tryptophyl-lysyl-valyl-cysteinyl)-threoninamide | angiopeptin | bim 23014 | bim-23014 | bim 23014c | bim-23014c | dc 13-116 | dc-13-116 | dc13-116 | ipstyl | lanreotide | lanreotide acetate | lanreotide autogel | lanreotide-sr | l-threoninamide, 3-(1-naphthalenyl)-d-alanyl-l-cysteinyl-l-tyrosyl-d-tryptophyl-l-lysyl-l-valyl-l-cysteinyl-, cyclic (2-7)-disulfide | l-threoninamide, 3-(2-naphthalenyl)-d-alanyl-l-cysteinyl-l-tyrosyl-d-tryptophyl-l-lysyl-l-valyl-l-cysteinyl-, cyclic (2-7)-disulfide | nal-cyclo(cys-tyr-trp-lys-val-cys)-thr-nh2 | nal-cyclo(cys-tyr-trp-lys-val-cys)thr-nh2 | naphthalenyl-cyclo(cysteinyl-tyrosyl-tryptophyl-lysyl-valyl-cysteinyl)threoninamide | naphthyl-cyclo(cys-tyr-trp-lys-val-cys)thr-nh2 | somatulin | somatulina | somatulin-autogel | somatuline | somatuline autogel | somatuline depot | somatuline la

Organizations (63)

Research & Development (61)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (37)

Approved Indications (2)


 

Acromegaly

Malignant Carcinoid Syndrome

Experimental Indications - Clinical Trial Phases 1-4 (37)


 

Acromegaly ()

Carcinoid Heart Disease (Phase 3)

Carcinoid Tumor (Phase 2)

Carcinoma (Phase 3)

Carcinoma, Hepatocellular (Phase 2/Phase 3)

Carcinoma, Merkel Cell (Phase 2)

Colorectal Neoplasms (Phase 3)

Congenital Hyperinsulinism (Phase 4)

Diarrhea (Phase 2/Phase 3)

Digestive System Diseases (Phase 3)

Dumping Syndrome (Phase 4)

Gastroesophageal Reflux (Phase 2)

Gastrointestinal Neoplasms (Phase 2)

Genetic Diseases, Inborn (Phase 2/Phase 3)

Graves Ophthalmopathy (Phase 2)

Growth Hormone-Secreting Pituitary Adenoma (Phase 3)

Hepatomegaly (Phase 2/Phase 3)

Hyperglycemia (Phase 2)

Intestinal Diseases (Phase 2)

Intestinal Neoplasms (Phase 3)

Intestinal Obstruction (Phase 3)

Liver Diseases (Phase 2/Phase 3)

Lung Neoplasms (Phase 3)

Lymphocele (Phase 3)

Malignant Carcinoid Syndrome (Phase 3)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 3)

Neuroendocrine Tumors (Phase 4)

Pancreatic Diseases (Phase 2)

Pancreatic Fistula (Phase 2)

Pancreatic Neoplasms (Phase 3)

Paraganglioma (Phase 2)

Peritoneal Neoplasms (Phase 3)

Pheochromocytoma (Phase 2)

Polycystic Kidney, Autosomal Dominant (Phase 3)

Polycystic Kidney Diseases (Phase 2/Phase 3)

Prostatic Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 72
  • # of Trial Organizations: 61

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue